NCT05686642招募中2 期
A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 30
- 主要终点
- Incidence Adverse Events
研究概览
简要总结
This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects aged between 18 and 80 years at screening;
- •Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment; 3.4 points ≤ NIHSS score ≤ 25 points at randomization;
- •4.Subjects who are able to receive the investigational drug within 24 hours after the onset of stroke; 5.Female subjects of childbearing potential or male subjects whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective contraceptive measures during the study period and for 3 months after the last dose; 6.All subjects sign the informed consent form by themselves or their guardians after receiving complete study information.
排除标准
- •Subjects have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018 during this onset period;
- •Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points;
- •Neurological signs have improved rapidly and spontaneously at screening;
- •Subjects who have used or are using protocol-prohibited medications after the onset;
- •Subjects with pre-stroke disability;
- •Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or imaging evidence for arterial aneurysm requiring treatment;
- •Massive infarction on imaging;
- •Patients who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate;
- •Systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg after active antihypertensive therapy;
- •Acute hemorrhage tendency;
- •Blood glucose level < 50 mg/dL or > 400 mg/dL;
- •Active visceral hemorrhage;
- •Lactating or pregnant subjects, or women of childbearing potential with positive pregnancy test results;
- •International normalized ratio > 1.7 or prothrombin time > 15 s;
- •Subjects with a history of serious hypersensitivity;
- •Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening;
- •Subjects who underwent any major surgery before screening;
- •Subjects with a history of active digestive ulcer before screening;
- •Subjects who experienced hemorrhagic disease before screening;
- •Subjects who underwent arterial puncture at the site not easy for hemostasis by compression before screening;
- •Serious hepatic impairment or serious renal insufficiency;
- •Subjects who have participated in another investigational study and used investigational product before screening;
- •Other conditions unsuitable for participation in this study determined by the Investigator.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
LT3001 Drug:high dose
Experimental
干预措施: LT3001 Drug:high dose (Drug)
LT3001 Drug:low dose
Experimental
干预措施: LT3001 Drug:low dose (Drug)
结局指标
主要结局
Incidence Adverse Events
时间窗: Approximately 2 years
Adverse event type, incidence, duration, correlation with study drug
次要结局
- Proportion of subjects by mRS（Modified Rankin Scale） score (0 - 2)(Day 30 and Day 90 after the first dose)
- Proportion of subjects with an NIHSS（National Institute of Health stroke scale ） score of ≤ 1 point and/or with a decrease of ≥ 4 points from baseline in NIHSS score(Day 14 after the first dose)
- Absolute change from baseline in NIHSS score(Day 3、Day 7、Day 14 and Day 30 after the first dose)
- Proportion of subjects with a BI（Barthel index） score of ≥ 95 points and ≥ 75 points(Day 30 and Day 90 after the first dose)
研究者
研究点 (30)
Loading locations...
相似试验
招募中
2 期
A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma PatientsDLBCLNCT06569485Sun Yat-sen University38
已完成
2 期
Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)Newly Diagnosed Multiple MyelomaNCT01936532Nantes University Hospital42
已完成
1 期
A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMultiple Myeloma in RelapseNCT03136653Molecular Partners AG33
已完成
2 期
First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerColorectal Cancer MetastaticNCT01163396Gruppo Oncologico del Nord-Ovest57
招募中
2 期
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung CancerNon-Small Cell Lung CancerNCT06623136Elpiscience (Suzhou) Biopharma, Ltd.40